Zimmer Biomet (ZBH) – Analysts’ Recent Ratings Changes

Zimmer Biomet (NYSE: ZBH) has recently received a number of price target changes and ratings updates:

• 10/7/2026 – Zimmer Biomet was upgraded by Barclays PLC to “hold”.
• 10/6/2026 – Zimmer Biomet is now covered by Barclays PLC. They set an “equal weight” rating and a $100.00 price target on the stock.
• 10/5/2026 – Zimmer Biomet had its “neutral” rating reaffirmed by Citigroup Inc..
• 9/28/2026 – Zimmer Biomet had its “market perform” rating reaffirmed by BMO Capital Markets.
• 9/14/2026 – Zimmer Biomet was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/25/2026 – Zimmer Biomet was upgraded by Zacks Research from “strong sell” to “hold”.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insiders Place Their Bets

In related news, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.